anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This disclosure provides a technology for managing elevated cytokine levels and the risk of cytokine storm in viral infection, exemplified by SARS-CoV-2, the virus that causes COVID-19. A special mixture of cannabidiol (CBD), tetrahydrocannabivarin (THCV), and cannabidivarin (CBDV) is extracted from the flowers and leaves of Cannabis sativa (industrial hemp). The purified oil is packed with a surfactant into small micelles, which considerably increases absorption by the gastrointestinal tract, resulting in higher potency and a more rapid onset of action. Daily treatment of patients infected with SARS-CoV-2 reduces the circulating level of the pro-inflammatory cytokines tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) by 25 to 50% or more. The level of circulating markers of ongoing inflammation, such as C reactive protein (CRP) and/or erythrocyte sedimentation rate (EST) are also reduced. This lowers the risk that the treated patient will suffer the adverse consequences of a cytokine storm, potentially helping the patient to clear the virus and return to good health.
Cervical cancer is the most prevalent malignant tumor of the female reproductive system in China, with an estimated 150,700 new cases and 55,700 new deaths annually. Concurrent chemoradiotherapy (CRT) remains the standard treatment for locally advanced cervical cancer (LACC). However, for high-risk LACC (HR-LACC) patients, the 2-year progression-free survival (PFS) rate is only 57%-62%, and the 5-year overall survival (OS) rate is 52%-64%, which are the leading causes of patient mortality. The KEYNOTE-A18 study demonstrated that the combination of pembrolizumab and CRT reduced the progression risk and death risk by 30% and 27%, respectively, for HR-LACC patients. Following this, the FDA approved pembrolizumab in combination with CRT for the treatment of newly diagnosed stages III-IVA cervical cancer in January 2024. Nevertheless, the high cost of pembrolizumab poses a significant barrier for patients in China. Toripalimab, the first domestically approved PD-1 inhibitor in China, has shown good safety and efficacy in previous studies and is more affordable. This phase II, single-arm, open-label study aims to evaluate the efficacy and safety of Toripalimab combined with CRT followed by Toripalimab maintenance therapy in 130 patients with stages III-IVA cervical cancer. The primary endpoint is the 2-year PFS. The study is expected to contribute to the implementation of precision and personalized treatment for HR-LACC in China, with the potential to improve patient survival rates and quality of life.
The present disclosure relates to pharmaceutical field, providing a hydrolyzed chicken sternal cartilage extract, method for producing the same and use thereof. The hydrolyzed chicken sternal cartilage extract has a type II collagen content of ≥50% and a chondroitin sulfate content of ≥20%. In China, a huge amount of livestock and poultry are consumed, and the total consumption almost reaches ¼ of the worldwide livestock and poultry consumption. Chicken sternal cartilage is one of the main by-products in broiler chicken processing. In the present disclosure, a hydrolyzed chicken sternal cartilage extract rich in type II collagen and chondroitin sulfate is obtained by using biological enzymatic hydrolysis technique. Experiments results show that the hydrolyzed chicken sternal cartilage extract produced by the present disclosure has a good anti-inflammatory effect and can be used to prepare medications for treating osteoarthritis.
PROBLEM TO BE SOLVED: To obtain a dentifrice capable of removing foreign materials adhering to teeth without burting tooth enamel. SOLUTION: Charcoal powder is used as a main material. This is mixed with a wetting agent, e.g. glycerol, a caking additive, e.g. sodium carboxymethylcellulose, other additives and water and the mixture is homogeneously kneaded. The charcoal powder is formulated in an amount of 10-40wt.% (a proportion based on the whole materials) and its grain size is to be 50μ-2mm.
BACKGROUND: Uterus transplantation (UTx) is an emerging treatment for uterine factor infertility. Determining the maximum tolerable cold ischemia time is crucial for successful UTx. However, the limit for cold ischemia in the uterus is unclear. This study aimed to examine cold ischemia's effects on mouse uteri and identify the maximum cold ischemia duration that uteri can endure.
METHODS: We systematically assessed the tolerance of mouse uteri to extended cold ischemia, 24 h, 36 h, and 48 h, using the cervical heterotopic UTx model. Multiple indicators were used to evaluate ischemia-reperfusion injury, including reperfusion duration, macroscopic examination, oxidative stress, inflammation, and histopathology. The function of transplants was evaluated through estrous cycle monitoring and embryo transfer.
RESULTS: Mouse uteri subjected to 48 h of cold ischemia exhibited significant delays and insufficiencies in reperfusion, substantial tissue necrosis, and loss of the estrous cycle. Conversely, uteri that underwent cold ischemia within 36 h showed long survival, regular estrous cycles, and fertility.
CONCLUSIONS: Our study demonstrated that mouse uteri can endure at least 36 h of cold ischemia, extending the known limits for cold ischemia and providing a pivotal reference for research on the prevention and treatment of cold ischemic injury in UTx.
Participants randomized to ATI will halt their ART medications starting 2 weeks (more or less 3 days) after the first imaging visit. This plan will be discussed with participants during the baseline visit. Patients will be contacted 1-3 days prior to ATI initiation. ATI may be delayed or cancelled if there are new safety concerns. HIV plasma viral levels and CD4 counts will be monitored every week during the ATI phase. If a participant meets any of the ART restart criteria during the ATI phase, then they will discontinue ATI and restart ART. Participants who do not meet restart criteria will remain off ART and continue to be monitored weekly until they have been on ATI for 90 days, and then will restart ART.
Placebo capsules containing an inactive ingredient. 2 capsules are swallowed once per day with water for 12 weeks. Looks identical to lycopene capsule.
The sunbathing group will receive all interventions prescribed for the control group and assign to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates will sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
Refractory sex hepatitis B is to point to although standard application nucleoside (acid) analogue treatment undertakes first treat and 2 strengthen treat cure, but existence is persistent viraemia. These patients have active liver inflammation and are at high risk for progression to cirrhosis or primary liver cancer due to persistent virus-positive symptoms. Therefore, it is of great significance to find an effective antiviral program for refractory hepatitis B to reduce the fatality rate of hepatitis B in China. At present, the guidelines recommend that patients with drug resistance to Entecavir (ETV) be treated with tenofovir fumarate (TDF) or propofol tenofovir fumarate (TAF), and clinical studies in China have confirmed that increased dosage of entecavir to 1.0mg can be used as the treatment of drug resistance to entecavir. TDF and TAF resistant patients can be treated with entecavir 0.5mg. However, currently there is no consensus on salvage treatment for patients who remain virus-positive after a second round of antiviral therapy. Previous studies have shown that TDF/TAF combined with ETV 1.0mg as a rescue regimen has no obvious adverse drug reactions. This is the first multicenter, prospective, parallel controlled, open-label cohort study to compare the efficacy and safety of TDF/TAF combined with ETV 1.0mg regimen versus continuation of the original regimen in the treatment of refractory hepatitis B. Meanwhile, long-term outcomes of refractory hepatitis B patients, such as survival, cirrhosis and primary liver cancer, were observed. In addition, the effects of refractory hepatitis B virus strain, host and other clinical characteristics on the antiviral efficacy of nucleoside (acid) analogue were compared with those of patients with initial treatment and secondary enhancement of nucleoside (acid) analogue response. The results of this study are expected to provide a new perspective for the treatment of refractory hepatitis B and provide direct evidence for the formulation of guidelines for the diagnosis and treatment of chronic hepatitis B in China and even internationally.
Vaginal candidiasis is the second infection of the genital tract after bacterial vaginosis. Up to 75% of women will have at least one episode in their lives, but the clinical manifestations can be very variable. Around 10 to 20% will be asymptomatic and 5 to 10% will have the recurrent candidiasis that means 4 or more episodes in a year. The predominant symptoms are pruritus in 89% and burning during urination and sexual intercourse in 66%. The therapeutic regimen for acute fungal infections by C. albicans should consider the intensity of the clinical symptoms, recurrence, patient preference for the route of administration and consequent adherence to treatment, presence of pregnancy and the possibility of side effects. In general, the schemes include anti-fungal substances of the azoles type. Intravaginal administration of drugs requires the development of formulations suited to the area and adherence to the treatment can be increased if mucoadhesive formulations are obtained which avoid discomfort and provide adequate release of the active compounds. In this sense, the present project had the objective of developing a mucoadhesive gel containing Propolis Standardized (EPP-AF®) for the treatment of vaginal candidiasis, especially since preclinical efficacy and safety data demonstrated the clinical potential of the product. So the present proposal aims at the clinical study evaluate the efficacy of two formulations with 1 and 2% of propolis in comparison with clotrimazole cream treatment (patients affected by Candidiasis) and also evaluate the safety of both propolis gels in healthy volunteers. The efficacy protocol of the test product in patients with vaginal candidiasis will be performed in an open-label, randomized, three-arm, clinical trial with active clotrimazole-based control. Patients will be recruited (T0) and evaluated at 10 and 30 days after initiation of treatment, and the primary outcome will be the clinical cure rate.
A vaccine for protection of humans against trachoma comprises purified virulent or attenuated living trachoma virus or inclusion blennorrhoea virus and an injectable pharmaceutical carrier or diluent.  The attenuated virus is obtained by many passages through a host such as thick embryos, tissue cultures and animal hosts.  It is preferred to cultivate the virulent or attenuated virus in thick embryos which are 6 to 8 days old at inoculation.  The embryos are inoculated via the yolk sac with a suspension in saline of yolk sac infected with the virus and containing streptomycin to prevent bacterial infection and are incubated at 35 DEG  C. until the yolk sac is rich in virus, any eggs dying within 72 hours of inoculation being rejected.  Infected yolk sacs free from bacteria are homogenized with phosphate buffered saline and centrifuged at 200 G for 5 minutes to remove impurities.  The supernatant is mixed with more phosphate buffered saline and centrifuged at 40 DEG  C. and 12,000 G to deposit the virus.  The process is repeated on the deposited virus to bring about further purification.  The virus is resuspended in phosphate buffered saline and mixed with sterile aqueous gelatine to give a final concentration of 10% aqueous gelatine.  When required for use, the freeze dried product is reconstituted with sterile pyrogen free water.  The gelatin is used to inhibit denaturation of the virus during freeze drying and may be replaced by dextran.  Specification 764,718 is referred to.
Investigational dose = 0.25 time of the expected dose. The drug should not be taken more than one time a day or 3 times a week Drug: TD0025 Administered orally once a day, 5 hours before sexual activity, for 1 month.
This invention relates generally to in vitro methods for inducing or enhancing expression of enteric bacterial antigens and/or virulence factors thereby producing antigenically enhanced enteric bacteria, to methods for using antigenically enhanced enteric bacteria and to vaccines comprising antigenically enhanced enteric bacteria. Further, a vaccine comprising a Campylobacter bacterium having en enhanced antigenic property is disclosed. The culture medium conditions comprise 0.05% to 3% bile or 0.025% to 0.6% of one or more bile acids or salts. In addition a divalent cation chelator can also be included in the culture medium. The bacteria culture is in a growth phase at early log phase and between early log phase and stationary phase. The enhanced antigenic property is a higher level of an immunogenic antigen when compared to the antigenic property of the same bacteria grown on brain heart infusion broth.
PURPOSE:To obtain a readily handleable granular sodium bicarbonate dialytic agent, containing an electrolytic ingredient under specific conditions, advantageous to storage or conveyance, capable of readily providing a sodium bicarbonate dialyzing fluid and having a high dissolution rate. CONSTITUTION:A sodium bicarbonate dialytic agent is prepared as follows. An electrolytic ingredient is divided into a group (agent A) containing no sodium bicarbonate and a group (agent B) containing the sodium bicarbonate. The sodium bicarbonate, sodium chloride and/or sodium acetate are contained in the agent (B) and water is suitably blended to granulate the agent (B). The amounts of the ingredients are 0.5-7wt.% sodium chloride and 0.3-10wt.% sodium acetate expressed in terms of anhydrous sodium acetate. A mixture of ingredients unblended in the agent (B) in ingredients necessary for the dialytic agent is granulated to afford the agent (A). In use, the agents (A) and (B) are mixed. The aforementioned dialytic agent is readily soluble in water to form a homogeneous aqueous solution and simply afford a dialyzing fluid. The dialytic agent is a drug for preparing the dialyzing fluid.
The invention relates to a network hospital system based on big data applications. The system comprises a sanitary bureau terminal, a hospital terminal, a doctor terminal and a client terminal. The sanitary bureau terminal is used for supervising the hospital terminal. The hospital terminal comprises a central processing unit used for extracting symptom and sign information, corresponding to different diseases, from electronic medical records stored in a database; generating pre-diagnosis information classification charts; and transmitting the classification charts to the client terminal. The client terminal is connected to the doctor terminal. The client terminal comprises a data transmission module. The data transmission module is used for receiving the pre-diagnosis information classification charts transmitted by the central processing unit, transmitting the pre-diagnosis information classification charts to a data display module, receiving personal symptom and sign information which is selected by the users according to the pre-diagnosis information classification charts, and sending the information to the doctor terminal. The data display module receives the pre-diagnosis information classification charts transmitted by the data transmission module, and displays the pre-diagnosis information classification charts so as to provide selection for the users. The invention further provides a data application method for the database in the network hospital system based on the big data applications, thereby bringing convenience for the users to use the system.
Idiopathic intracranial hypertension (IIH) is a diagnosis of exclusion characterized by features of raised intracranial pressure (ICP) in the absence of brain parenchymal lesion, vascular malformations, hydrocephalus, or central nervous system (CNS) infection. Commonly used other terms for this entity include benign intracranial hypertension (BIH) or pseudotumor cerebri. Few case reports of systemic lupus erythematosus (SLE) presenting as IIH are available in the literature. We report a 12-year-old girl presented with chronic holocranial headache and occasional episodes of projectile vomiting for the last 6 months and then developed blurring of vision for the last month. She fulfilled the criteria for IIH. Subsequent evaluation revealed a diagnosis of SLE. The occurrence of IIH in SLE is not coincidental and is reported in 1%-5.4% of patients with SLE. Though corticosteroids have not been widely used in IIH, underlying SLE warranted administering corticosteroids with subsequent complete resolution of IIH. Pediatricians, neurologists, intensivists, and ophthalmologists should consider SLE as a differential diagnosis in children presenting with IIH.
A system for monitoring cardiac health of a user including a local sensing subsystem, a contactless interrogation subsystem, and a remote monitoring subsystem. The local sensing subsystem may include a sensor patch configured to attach to the user and include a substrate, a passive radio-frequency identification transponder, and a first antenna. The contactless interrogation subsystem may include an interrogator separated from the sensor patch, which may include a second antenna, a demodulator, and a communications link. The remote monitoring subsystem may include a computing system comprising a processor for executing instructions. The local sensing subsystem may be adapted to perform at least one scan. The contactless interrogation subsystem may be adapted to operate the demodulator to receive a cardiac event and to operate the communications link to transmit the cardiac event. The remote monitoring subsystem may be adapted to execute the instructions to detect an arrhythmia from the cardiac reading.
The active ingredient in famotidine tablets USP is a histamine-2 (H 2) receptor antagonist. Famotidine is N′‑(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio] propanimidamide. The molecular formula of famotidine is C 8H 15N 7O 2S 3 and its molecular weight is 337.43. Its structural formula is: 

Each famotidine tablet for oral administration contains either 20 mg or 40 mg of famotidine USP and the following inactive ingredients: carnauba wax, corn starch, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, talc, and titanium dioxide. In addition the 20 mg tablets contain red iron oxide, and yellow iron oxide.

Famotidine USP is a white to pale yellowish white crystalline powder that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol.
There is no well documented experience with glipizide overdosage. The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg).

Overdosage of sulfonylureas, including glipizide, can produce hypoglycemia. Mild hypoglycemic symptoms without loss of consciousness or neurologic findings should be treated aggressively with oral glucose and adjustments in drug dosage and/or meal patterns. Close monitoring should continue until the physician is assured that the patient is out of danger. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment occur infrequently, but constitute medical emergencies requiring immediate hospitalization. If hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous injection of concentrated (50%) glucose solution. This should be followed by a continuous infusion of a more dilute (10%) glucose solution at a rate that will maintain the blood glucose at a level above 100 mg/dL. Patients should be closely monitored for a minimum of 24 to 48 hours since hypoglycemia may recur after apparent clinical recovery. Clearance of glipizide from plasma would be prolonged in persons with liver disease. Because of the extensive protein binding of glipizide, dialysis is unlikely to be of benefit.
The invention aims to disclose a traditional Chinese medicine compound for treating empyrosis and scald. The traditional Chinese medicine compound is called as Huangcha solution for short. The crude drug of the compound includes cortex phellodendri, coptis chinensis, scutellaria baicalensis and tea leaves. A method comprises the following steps: weighting the crude drug and then milling into powder; putting into 500ml sesame oil; steaming for a half hour; leaching out a thick juice; putting into a bottle and then steaming for a half hour; cooling and then coating to an affected part; coating for 8 times per 24 hours; after the wound is scabbed, adding less coix seed powder into normal saline, decocting and boiling, and then cooling and coating to a scabbing part; and coating the medicine after the scabbed skin falls off, till healing. The traditional Chinese medicine compound prepared according to the invention is a decoction, is in block yellow color, has a bitter and fragrant flavor, tastes bitter and astringent, has the effects of clearing away heat and toxic materials, diminishing inflammation and promoting granulation and has the advantages of low cost, fast effectiveness, safety, and the like. The traditional Chinese medicine compound for treating empyrosis and scald has three effects of diminishing inflammation, relieving pain and removing scar.
Candida auris has become a serious threat to public health. The mechanisms of how this fungal pathogen adapts to the mammalian host are poorly understood. Here we report the rapid evolution of an adaptive C. auris multicellular aggregative morphology in the murine host during systemic infection. C. auris aggregative cells accumulate in the brain and exhibit obvious advantages over the single-celled yeast-form cells during systemic infection. Genetic mutations, specifically de novo point mutations in genes associated with cell division or budding processes, underlie the rapid evolution of this aggregative phenotype. Most mutated C. auris genes are associated with the regulation of cell wall integrity, cytokinesis, cytoskeletal properties, and cellular polarization. Moreover, the multicellular aggregates are notably more recalcitrant to the host antimicrobial peptides LL-37 and PACAP relative to the single-celled yeast-form cells. Overall, to survive in the host, C. auris can rapidly evolve a multicellular aggregative morphology via genetic mutations.